Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;29(3):761-769.
doi: 10.1111/hae.14769. Epub 2023 Mar 15.

Trends in prescribing practices for management of haemophilia: 1999-2021

Randall Curtis  1 , Jonathan C Roberts  2 , Nicole Crook  3 , Marquita Decker-Palmer  4 , Rahul Khainar  4 , Judith R Baker  3 , Megan Ullman  5 , Marion A Koerper  6 , Joanne Wu  7 , Michael B Nichol  7
Affiliations

Trends in prescribing practices for management of haemophilia: 1999-2021

Randall Curtis et al. Haemophilia. 2023 May.

Abstract

Introduction: People with haemophilia rely on specialists for their care, yet the specific dosing regimens of treatments prescribed by these specialists have not been widely studied.

Aim: The objective of this study is to describe trends in clinician prescribing practices for the management of haemophilia in the United States (US).

Methods: We administered surveys to members of the Hemostasis and Thrombosis Research Society via paper surveys at its in-person annual symposia in 1999 and 2015, and an online survey in 2021. The surveys collected information on haemophilia treatments including factor dosing, inhibitor therapy and gene therapy.

Results: Clinicians treating haemophilia for more than 50% of their practice time have increased from 37.5% of respondents in 1999 to 46.3% in 2021. Clinicians prescribing factor concentrates at >40 units/kg for routine bleeding events increased from 0% in 1999 to 29.3% in 2021 in haemophilia A (HA) and from 22.5% to 87.8% in haemophilia B (HB). In 2021, the clinicians reported prescribing emicizumab to treat HA patients (>89.5% paediatric, >85.7% adult) with or without inhibitors at least some of the time. Approximately 78.0% of respondents reported that they expected to recommend gene therapy at least some of time.

Conclusion: These data indicate changing trends in prescribing practices among US haemophilia specialists during the past 22 years. Preference for high doses of factor (>40 units/kg) has increased during this period. Emicizumab prophylaxis has been prescribed for patients with and without HA inhibitors. Clinicians expect gene therapy to have value for some haemophilia patients.

Keywords: clotting factor dose trend; emicizumab; haemophilia; inhibitor; prescribing practices; prophylaxis.

PubMed Disclaimer

References

REFERENCES

    1. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med. 2007;357(6):535-544.
    1. Loomans JI, Eckhardt CL, Reitter-Pfoertner SE, et al. Mortality caused by intracranial bleeding in non-severe haemophilia A patients. J Thromb Haemost. 2017;15(6):1115-1122.
    1. Rodriguez-Merchan EC. Articular bleeding in haemophilia. Cardiovasc Hematol Disord Drug Targets. 2016;16(1):21-24.
    1. Matuk-Villazon O, Roberts JC, Corrales-Medina FF, Hemophilia: the past, the present, and the future. Pediatr Rev. 2021;42(12):672-683. doi:10.1542/pir.2020-004143
    1. Baker JR, Riske B, Drake JH, et al. US haemophilia treatment center population trends 1990-2010: patient diagnoses, demographics, health services utilization. Haemophilia. 2013;19(1):21-26.

Grants and funding

LinkOut - more resources